Skip to main
  1. Stocks
  2. Mobia Medical Inc
  3. Forecast
MOBI

MOBI Stock Forecast & Price Target

MOBI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mobia Medical is supported by a rare first-mover advantage as the first and only FDA-approved VNS platform for chronic ischemic stroke recovery, addressing a large unmet need among roughly 9 million ischemic stroke survivors. Clinical evidence is strengthening, with the VNS-REHAB study showing 76% of participants achieved a clinically meaningful response, average FMA-UE gains of +7.5 points, and durable improvements that continued between years one and two. Commercial traction is also accelerating, as 2Q26 revenue reached $13.5 million, up 102% year over year, with active territories rising to about 35.5 and management guiding FY26 sales of $54 million to $56 million.

Bears say

Mobia Medical is exposed to meaningful execution risk because its valuation depends almost entirely on adoption of Vivistim, and slower uptake by fewer new stroke centers than modeled would directly weaken revenue growth. Additional pressure could come from lower overall market growth rates and faster ASP degradation than assumed, which would compress sales and margins since the company generates all of its revenue from Vivistim system sales. The outlook is further challenged by longer product development timelines and higher operating expense spend than modeled, both of which could delay profitability and increase cash burn.

MOBI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mobia Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

MOBI Analyst Forecast & Price Prediction

Get the latest MOBI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MOBI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mobia Medical Inc (MOBI) Forecast

Analysts have given MOBI a Strong Buy based on their latest research and market trends.

According to 4 analysts, MOBI has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mobia Medical Inc (MOBI)


MOBI Analyst Forecast & Price Prediction

Get the latest MOBI stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MOBI

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MOBI stock data and trends